دورية أكاديمية
Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
| العنوان: | Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk. |
|---|---|
| المؤلفون: | Kader AK; Department of Urology, Moores Cancer Center, University of California San Diego, San Diego, CA. Electronic address: kkader@ucsd.edu., Liss MA; Department of Urology, Moores Cancer Center, University of California San Diego, San Diego, CA., Trottier G; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada., Kim ST; Departments of Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC., Sun J; Departments of Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC., Zheng SL; Departments of Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC., Chadwick K; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada., Lockwood G; Canadian Partnership Against Cancer, Toronto, Canada., Xu J; Departments of Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC., Fleshner NE; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada. |
| المصدر: | Urology [Urology] 2015 Jan; Vol. 85 (1), pp. 165-70. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 0366151 Publication Model: Print Cited Medium: Internet ISSN: 1527-9995 (Electronic) Linking ISSN: 00904295 NLM ISO Abbreviation: Urology Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York : Elsevier Science Original Publication: Ridgewood, N.J., Professional Medical Services Co. |
| مواضيع طبية MeSH: | Prostate-Specific Antigen/*blood , Prostatic Neoplasms/*blood , Prostatic Neoplasms/*diagnosis, Adult ; Aged ; Aged, 80 and over ; Biopsy ; Genetic Predisposition to Disease ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/genetics ; Risk Assessment ; Risk Factors |
| مستخلص: | Objective: To determine to what extent prostate cancer (PCa) risk prediction is improved by adding prostate-specific antigen (PSA) to a baseline model including genetic risk. Methods: Peripheral blood deoxyribonucleic acid was obtained from Caucasian men undergoing prostate biopsy at the University of Toronto (September 1, 2008 to January 31, 2010). Thirty-three PCa risk-associated single nucleotide polymorphisms were genotyped to generate the prostate cancer genetic score 33 (PGS-33). Primary outcome is PCa on study prostate biopsy. Logistic regression, area under the receiver-operating characteristic curves (AUC), and net reclassification improvement were used to compare models. Results: Among 670 patients, 323 (48.2%) were diagnosed with PCa. The PGS-33 was highly associated with biopsy-detectable PCa (odds ratio, 1.66; P = 5.86E-05; AUC, 0.59) compared with PSA (odds ratio, 1.33; P = .01; AUC, 0.55). PSA did not improve risk prediction when added to a baseline model (age, family history, digital rectal examination, and PGS-33) for overall risk (AUC, 0.66 vs 0.66; P = .86) or Gleason score ≥7 PCa (AUC, 0.71 vs 0.73; P = .15). Net reclassification improvement analyses demonstrated no appropriate reclassifications with the addition of PSA to the baseline model for overall PCa but did show some benefit for reclassification of men thought to be at higher baseline risk in the high-grade PCa analysis. Conclusion: In a baseline model of PCa risk including the PGS-33, PSA does not add to risk prediction for overall PCa for men presenting for "for-cause" biopsy. These findings suggest that PSA screening may be minimized in men at low baseline risk. (Copyright © 2015 Elsevier Inc. All rights reserved.) |
| التعليقات: | Comment in: Urology. 2015 Jan;85(1):170-1. (PMID: 25530380) Comment in: Urology. 2015 Jan;85(1):171. (PMID: 25530381) |
| References: | Cancer Causes Control. 2008 Mar;19(2):175-81. (PMID: 18027095) N Engl J Med. 2004 May 27;350(22):2239-46. (PMID: 15163773) Clin Cancer Res. 2009 May 1;15(9):3231-7. (PMID: 19366831) Ann Intern Med. 2012 Jul 17;157(2):120-34. (PMID: 22801674) Eur Urol. 2011 Jul;60(1):21-8. (PMID: 21295399) N Engl J Med. 2009 Mar 26;360(13):1310-9. (PMID: 19297565) N Engl J Med. 2008 Jun 26;358(26):2796-803. (PMID: 18579814) Eur J Cancer. 2011 Dec;47(18):2698-705. (PMID: 21788129) Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12. (PMID: 17569110) N Engl J Med. 2012 Jul 19;367(3):203-13. (PMID: 22808955) Prostate. 2009 Mar 1;69(4):363-72. (PMID: 19058137) CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. (PMID: 22237781) Lancet Oncol. 2010 Aug;11(8):725-32. (PMID: 20598634) Biometrics. 1988 Sep;44(3):837-45. (PMID: 3203132) Prostate. 2009 Oct 1;69(14):1565-72. (PMID: 19562736) N Engl J Med. 2008 Feb 28;358(9):910-9. (PMID: 18199855) Cancer. 2011 Mar 15;117(6):1210-9. (PMID: 20960520) N Engl J Med. 2009 Mar 26;360(13):1320-8. (PMID: 19297566) Eur Urol. 2012 Dec;62(6):953-61. (PMID: 22652152) Eur Urol. 2012 Mar;61(3):471-7. (PMID: 22101116) Prostate. 2010 Dec 1;70(16):1729-38. (PMID: 20564319) Eur Urol. 2010 Jan;57(1):79-85. (PMID: 19733959) |
| معلومات مُعتمدة: | RC2 CA148463 United States CA NCI NIH HHS; UC2 CA148463 United States CA NCI NIH HHS; CA148463 United States CA NCI NIH HHS |
| المشرفين على المادة: | EC 3.4.21.77 (Prostate-Specific Antigen) |
| تواريخ الأحداث: | Date Created: 20141223 Date Completed: 20150223 Latest Revision: 20181113 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC5398897 |
| DOI: | 10.1016/j.urology.2014.07.081 |
| PMID: | 25530379 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1527-9995 |
|---|---|
| DOI: | 10.1016/j.urology.2014.07.081 |